Rare Sarcomas

Clear cell sarcoma.- Epithelioid sarcoma.- PEComa.- Desmoplastic small round cell tumour.- Malignant solitary fibrous tumour.- Alveolar soft part sarcoma.- Epithelioid Hemangioendothelioma.- Low grade fibromyxoid sarcoma/sclerosing epithelioid fibrosarcoma.- New Born and Infant Soft Tissue Sarcomas.

Dr Christine Chevreau is the head of the sarcoma unit at the Oncopole Toulouse (France) a referral center for the management of sarcomas. Dr Chevreau is board certified in medical oncology and obtained her medical degree from the University of Toulouse in 1985. She is a recognized expert in the field of sarcomas and urological tumors and has been involved as principal investigator or co-investigator in more than 50 clinical trials. She authored or co-authored more than 180 publications including papers as first or last author in the Journal of Clinical Oncology, Cancer and the European Journal of Cancer. Pr Antoine Itaiano is the head of the Early Phase Trials and Sarcoma Units at Institut Bergonié (Bordeaux, France), national coordinating reference center for the diagnosis and management of sarcomas in France. Pr Italiano trained as a medical oncologist and obtained the Best Medical Thesis Price from Nice Medical School in 2005. He gained a PhD degree in Molecular Aspects of Cell Biology in 2008 and completed his training with a post-doctoral fellowship in the laboratory of Cristina Antonescu at Memorial Sloan Kettering Cancer center, New York, USA. His main research interests are in early clinical development, phase I trials across solid tumors, pharmacodynamic biomarkers, early phase II trials and sarcoma. He is also involved in translational research aspects related to sensitivity and resistance to targeted therapies, notably in soft-tissue sarcoma models. Pr Italiano has been the Principal Investigator of more than 20 phase I trials during the past 5 years as well as a dozen phase II and phase III trials in sarcomas. Dr Italiano is member of ASCO, AACR, and ESMO. He is peer reviewer for several oncology journals and has contributed to over 150 peer-reviewed publications, including publications as first or last author in the Lancet Oncology, Journal of Clinical Oncology, Clinical Cancer Research and Annals of Oncology. He mentored since 2008 4 medical students